Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NexMed, a company into CRO business and seeking to leverage its proprietary, multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, has recruited Mohamed Hachicha as a vice president of research and development for NexMed USA, effective immediately.
Subscribe to our email newsletter
Before being appointed in NexMed Dr Hachicha worked as a senior principal scientist in the pharmacology and drug discovery department at Forest Laboratories, from 2005 to 2010, where he took up the responsibility of managing and coordinating two of the company’s discovery research programs.
Prior to this, from 1999 to 2005, he was principal investigator in the molecular pharmacology department at Purdue Pharma, where he was held responsible to manage and coordinate the company’s multi-disciplinary discovery research program.
Bassam Damaj, president and CEO of NexMed, said: “Dr Hachicha’s experience in the field of drug development, from target identification and validation to the selection of clinical development targets, made him fit the role of vice president, research and development for NexMed USA.
“Dr Hachicha’s expertise is expected to be instrumental as we move ahead with our strategy to maximise the possibilities for the NexACT technology.”